

# MI-773

Catalog No: tcsc2686



## Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



## Specifications

### CAS No:

1303607-07-9

### Formula:

$C_{29}H_{34}Cl_2FN_3O_3$

### Pathway:

Apoptosis

### Target:

MDM-2/p53

### Purity / Grade:

>98%

### Solubility:

DMSO :  $\geq 53$  mg/mL (94.22 mM)

### Observed Molecular Weight:

562.5

## Product Description


MI-773 is a new small molecule inhibitor of the **MDM2-p53** interaction, binds to **MDM2** with high affinity ( $K_i=0.88$  nM) and blocks

the p53-MDM2 interaction.

IC50 & Target: Ki: 0.88 nM (MDM2)<sup>[1]</sup>

**In Vitro:** MI-773 potently induces expression of p53 and its downstream targets p21, MDM2, and induces phosphorylation of p53 (serine 392) in low passage primary human ACC cells. Notably, MI-773 induces a dose-dependent increase in the fraction of apoptotic ACC cells and in the fraction of cells in the G1 phase of cell cycle (P[1]. MI-773 is an advanced synthetic small molecule inhibitor, displays high binding affinity against MDM2 ( $K_d=8.2$  nM)<sup>[2]</sup>.

**In Vivo:** MI-773 at 10 mg/kg modestly reduces the rate of tumor growth, whereas 100 mg/kg causes significant tumor regression. Control tumors reach an average of 1,000 mm<sup>3</sup> at 20 days of treatment, compare to an average volume of 600 mm<sup>3</sup> for the 10 mg/kg group and 30 mm<sup>3</sup> for the 100 mg/kg group. Kaplan-Meier analysis shows an increase in tumor failure, define as two times increase in tumor volume as compared to pretreatment volume (P=0.044), for vehicle-treated mice when compare to mice treated with 100 mg/kg MI-773<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!